This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
I-DXd
ESMO 2025 | October 17-21, 2025
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
A randomized phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Mini-Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
Datopotamab deruxtecan (Dato-DXd) + rilvegostomig in patients with locally advanced or metastatic urothelial cancer: Results from the phase 2 TROPION-PanTumor03 study
Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as
first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer: Results from arms 7 and 8 of the phase 1b/2 BEGONIA study
Oral
T-DXd
ESMO 2025 | October 17-21, 2025
DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs ddAC-THP for high-risk HER2+ early breast cancer
Oral
Pipeline Compounds
ESMO 2025 | October 17-21, 2025
DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate, in patients with advanced/metastatic solid tumors: Initial results from a first-in-human study
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Final real-world safety and effectiveness results of REALITY-01 study: Trastuzumab deruxtecan (T-DXd) in patients received ≥ 2 prior treatment lines for HER2+ metastatic or unresectable (m/u) breast cancer (BC)
Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in
patients with locally recurrent inoperable or metastatic triple-negative
breast cancer (TNBC) for whom immunotherapy was not an option:
Primary results from the randomised, phase 3 TROPION-Breast02 trial
Poster
HER3-DXd
ESMO 2025 | October 17-21, 2025
HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan (HER3-DXd) plus pembrolizumab before or after pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer (TNBC) or hormone receptor–low positive (HR-low+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer
Mini-Oral
I-DXd
ESMO 2025 | October 17-21, 2025
Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer and baseline brain metastases: Primary analysis of IDeate-Lung01